Among thyroid neoplasms, Hurthle cell tumors (HCTs) have traditionally been a distinct diagnostic category. Hurthle cell adenomas are encapsulated follicular lesions with benign behavior. Hurthle cell carcinomas exhibit unequivocal capsular and/or vascular invasion; they are aggressive tumors with a poor prognosis. Recently, Hurthle cell papillary thyroid carcinomas (PTCs) have been identified on morphological grounds. We hypothesize that a subset of HCTs represent PTC with clinical, histological, and immunohistochemical features based on specific molecular events. ret/PTC gene rearrangements give rise to novel oncogenes that are unique to PTC. We studied a group (n ϭ 50) of HCTs for ret/PTC gene rearrangements. Tumors were examined for papillary differentiation by light microscopic evaluation of nuclear features, by RT-PCR for ret/PTC gene rearrangements, and by immunohistochemistry for ret. Among 24 noninvasive tumors, 13 contained ribonucleic acid for ret/PTC-1, -2, or -3, and 9 of these were immunoreactive for ret. Among 19 Hurthle cell carcinomas, 15 had focal nuclear hypochromasia with grooves and/or inclusions; expressed transcripts of ret/PTC-1, -2, or -3; and exhibited ret positivity. Tumors with ret/PTC gene rearrangements tended to have lymph node metastases rather than hematogenous spread. Our results indicate that a subset of HCTs exhibit features of PTC that are attributable to specific gene rearrangements, resulting in expression of ret/PTC oncogenes. These data support subclassification of HCTs into three groups: Hurthle cell adenomas, Hurthle cell carcinomas, and Hurthle cell PTC. (J Clin Endocrinol Metab 85: 878 -882, 2000) 
T HYROID TUMORS derived from follicular epithelial cells are classified as benign adenomas, malignant well differentiated papillary or follicular carcinomas, poorly differentiated or insular carcinomas, and undifferentiated or anaplastic carcinomas (1, 2) . Papillary thyroid carcinoma was originally defined, as its name suggests, based on an architectural pattern that predicted a unique biological behavior characterized by indolent growth, lymphatic spread, and a good prognosis. Subsequently, it was recognized that the biology of this lesion correlated with distinctive nuclear features, including elongation, hypochromasia with peripheral margination of chromatin, micronucleoli, and irregular contours with grooves and cytoplasmic pseudoinclusions (1, 3, 4) .
Recently, the molecular basis of papillary carcinoma has been further elucidated by the identification of a family of gene rearrangements, called ret/PTC (5, 6 ) that involve the ret protooncogene on chromosome 10. This gene, which is not normally expressed in follicular epithelium, is rearranged in papillary thyroid carcinoma (PTC) (7) ; the cytoplasmic domain of ret is expressed under the control of one of three other promoters (H4, R1␣, or ele1) that are ubiquitously expressed in thyroid follicular epithelium (8 -10) . ret/ PTC-1 has been shown to be oncogenic, in that it contains a constitutively active tyrosine kinase (11, 12) , it transforms NIH-3T3 fibroblasts (5) , and thyroid-targeted expression in transgenic mice results in tumor development (13, 14) . Moreover, transfection of this oncogene into cultured primary human thyroid cells results in nuclear alterations consistent with the cytological features of PTC (15) .
Hurthle cells are mitochondrion-rich follicular epithelial cells that produce thyroglobulin. Hurthle cell thyroid tumors are defined as being composed of at least 75% Hurthle cells (1, 2) . Some investigators believe that they are distinct from other follicular cell neoplasms (1), whereas others consider them to be subtypes of follicular lesions (2, 4) . In either case, they are classified as benign [Hurthle cell adenomas (HCA)] or malignant [Hurthle cell carcinomas (HCC)]. These two entities are distinguished based on the identification of capsular or vascular invasion, or on the presence of metastatic disease (1, 2, 4). However, they remain controversial because of their sometimes unexpected behavior (2, 16, 17) .
Several reports have described papillary carcinomas composed of Hurthle cells (18 -22) . These lesions all have papillary architecture. However, as the concept of papillary carcinoma has been expanded to identify well delineated lesions with follicular architecture and characteristic nuclear features, we hypothesized that there are also Hurthle cell tumors (HCT) that would be classified as HCA but are truly follicular variant papillary carcinomas composed of Hurthle cells. Although the nuclear hyperchromasia of Hurthle cells may mask the nuclear hypochromasia upon which the diagnosis would rely, the metaplastic process should not obscure the molecular basis of such a lesion.
We also hypothesized that the variable behavior of HCC could be explained by the presence of tumors that behave as either papillary or follicular carcinomas. However, in this group of tumors also, the identification of papillary carci-nomas composed of solid nests of Hurthle cells would require a molecular marker rather than a characteristic nuclear morphology. We therefore have analyzed a group of HCT to determine whether they harbor ret/PTC gene rearrangements that could predict a molecular classification of Hurthle cell papillary carcinoma.
Materials and Methods Materials
We collected 50 HCT from the files of the Department of Pathology and Laboratory Medicine at the Mount Sinai Hospital (Toronto, Canada) from 1993-1998. Selection was determined by the presence of at least 75% Hurthle cells in the tumor and the availability of material for analysis.
Histology
Tissues fixed in neutral buffered formalin were totally embedded in paraffin in 3-to 4-mm blocks, and 4-m thick sections were stained with hematoxylin and eosin for histological examination. The nuclear and architectural features were carefully evaluated, and immunohistochemistry was performed for ret (23) .
Ribonucleic acid (RNA) extraction
For molecular analysis, tumor tissue from most samples was snapfrozen in liquid nitrogen and stored at Ϫ80 C. Frozen sections confirmed the presence of lesional tissue in all samples. Frozen tumor tissue was crushed in liquid nitrogen and denatured in a solution containing 4 mol/L guanidine thiocyanate, 25 mmol/L sodium citrate, 0.5% Sarkosyl, and 0.1 mol/L ␤-mercaptoethanol. The samples were then sonicated for 30 s. The following solutions were added, mixed, and allowed to sit at 4 C for 10 min: 0.1 vol 2 mol/L sodium acetate (pH 5) in diethylpyrocarbonate (DEPC) water, 1 vol phenol, and 0.2 vol chloroform. After cold (4 C) centrifugation at 14,000 ϫ g for 20 min, 0.025 vol 1 n acetic acid and 0.5 vol cold (Ϫ20 C) ethanol were added to the samples; overnight precipitation followed. After cold (4 C) centrifugation for 25 min at 14,000 ϫ g, the pellet was washed with 70% ethanol, air-dried, and resuspended in 20 L DEPC water containing ribonuclease inhibitor.
In cases where frozen tissue was not available, paraffin blocks containing tumor were sectioned to obtain tissue for RNA extraction. The microtome blade was cleaned between samples to prevent contamination from one specimen to the next. Sections 20 m thick were deparaffinized in 1 mL xylene at room temperature for 20 min and washed once with 100% ethanol. After centrifugation, the pellet was air-dried and resuspended in 200 L of solution containing 6 mg/mL proteinase K (Sigma Canada Ltd., Oakville, Canada), 1 mol/L guanidine thiocyanate, 25 mmol/L ␤-mercaptoethanol, 0.5% Sarcosyl, and 20 mmol/L Tris (pH 7.5) and incubated at 58 C for 3.5 h with agitation. One equivalent volume of 70% phenol/30% chloroform was added and allowed to sit at 4 C for 20 min. This was followed by cold (4 C) centrifugation at 14,000 ϫ g. One volume of isopropanol and 2 g glycogen were added to the aqueous supernatant; overnight precipitation at Ϫ20 C followed. After cold (4 C) centrifugation for 25 min at 14,000 ϫ g, the pellet was washed with 70% ethanol, air-dried, and resuspended in 10 L DEPC water containing ribonuclease inhibitor. 
RT-PCR
Negative controls performed with each RT-PCR reaction omitted either template or reverse transcriptase. The products were resolved on a 1.2% agarose gel containing ethidium bromide and visualized under UV light.
Southern hybridization
PCR products were transferred to nylon membranes (Roche, Laval, Canada) by upward capillary action in 20 ϫ SSC followed by UV crosslinking. Complementary DNA probes (provided by Dr. S. Jhiang, Columbus, OH) were labeled with digoxigenin as previously described (23) . Labeling, hybridization, and detection were performed according to manufacturer's protocol (Roche).
Immunohistochemistry
Immunostaining was performed as described previously (23) using a rabbit polyclonal IgG antibody to the carboxyl-terminus of RET (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); negative controls replaced primary antiserum with nonimmune rabbit serum. Tissue sections cut at 4-m thickness were pretreated with 45% formic acid for 15 min at room temperature. After blocking endogenous peroxidase and nonspecific binding, the primary antibody at a dilution of 1:1000 was incubated at room temperature overnight, followed by detection with the ultrastreptavidin system (Signet, Dedham, MA).
Results

Patient and tumor characteristics
The patients included 38 women and 12 men, aged 24 -79 yr. There were 3 papillary carcinomas with classical papillary architecture in which the papillae were lined by cells with abundant eosinophilic granular cytoplasm (Fig. 1a) ; 1 of these had abundant stromal lymphoplasmacytic infiltration, consistent with a Warthin's-like papillary carcinoma (Fig. 1b) (21) . According to the current AFIP classification (1), the remaining lesions would have been classified as 24 HCA (Fig.  1c), 19 HCC (Fig. 1d) , and 4 Hurthle cell papillary neoplasms that had papillary architecture.
Ret/PTC expression
Among the 50 HCTs, 34 expressed a ret/PTC gene rearrangement; a representative Southern hybridization for each rearrangement of ret/PTC-1, -2, and -3 is shown in Fig. 2 . All 3 papillary carcinomas were positive; all 3 contained ret immunoreactivity. Of 24 tumors with features of HCA, 13 contained RNA for ret/PTC-1, -2 or -3, and 9 of these tumors were immunoreactive for ret (Fig. 1e) . Among 19 HCC, 15 expressed ret/PTC messenger RNA (mRNA), and 13 of these were immunohistochemically positive for ret (Fig. 1f) . Three of 4 Hurthle cell papillary neoplasms expressed ret/PTC mRNA transcripts, and 2 were positive for ret by immunohistochemistry.
Ret/PTC-1 rearrangements were the most common, identified in 17 tumors, but there were 15 tumors with ret/PTC-3 rearrangements. Ret/PTC-2 mRNA was found in 6 tumors. 
Clinical features of HCTs with ret/PTC expression
Among the tumors that expressed ret/PTC, five had lymph node metastases documented histologically at the time of initial surgery, confirming the diagnosis of malignancy. Two additional patients, whose tumors were noninvasive Hurthle cell neoplasms with follicular architecture, developed lymph node metastases that were confirmed on subsequent radioactive iodine scan. The only tumor in this series with disseminated malignancy was a HCC that did not express ret/PTC.
Discussion
Hurthle cell variants of PTC have been described in the literature (18 -22) ; they are more accurately described as Hurthle cell neoplasms with papillary architecture because the diagnosis relied primarily on architectural features. However, in tumors composed of follicular cells that do not exhibit Hurthle cell metaplasia, nuclear features are now accepted as the true diagnostic criteria for the diagnosis of PTC (1, 2, 4). Berho and Suster recognized this and proposed that the diagnosis of Hurthle cell papillary carcinoma should be based primarily on nuclear features (26) . In the majority of our HCT, careful histological examination usually revealed focal nuclear features of papillary carcinoma. Only four of our cases would have been identified had we relied on the criteria of papillary architecture alone.
The nuclear hyperchromasia that often accompanies Hurthle cell metaplasia may obscure the diagnostic nuclear features of papillary carcinoma. Therefore, the diagnosis of Hurthle cell papillary carcinoma requires an alternative diagnostic marker. Ret/PTC oncogene expression is unique to PTC and has been found with varying prevalence from 5-87% (24, 27, 28) . These numbers probably reflect differences in technique, patient population, and radiation exposure. Using RT-PCR with Southern hybridization, as we did, recent analyses have identified ret/PTC rearrangements in up to 77% of conventional papillary carcinomas (23) . Our current study represents the first report of ret/PTC expression in HCT. We demonstrate ret/PTC expression by RT-PCR in 34 of 50 HCT. It remains possible that more of these lesions are indeed papillary carcinomas that do not harbor one of the known ret/PTC gene rearrangements, and other markers, such as high molecular weight cytokeratins (29) , may prove useful as adjunctive tools for the diagnosis of Hurthle cell PTC.
In our study, ret/PTC-1 was the most common rearrangement, followed by ret/PTC-3; ret/PTC-2 was the least frequent. Ret/PTC-1 is the most frequent ret/PTC rearrangement in papillary carcinomas in North America (23, 24) ; only in children exposed to nuclear fallout after the Chernobyl explosion is the distribution different, and ret/PTC-3 is the most common rearrangement (27, 28) . In those children, there is a correlation between ret/PTC-3 expression and solid variant morphology as well as more aggressive behavior (28) . Interestingly, the number of tumors with ret/PTC-3 rearrangements was relatively high in our patients. Although morphology of the tumors did not correlate with ret/PTC gene rearrangements, it is interesting that 6 of the 15 tumors with ret/PTC-3 mRNA had solid architecture. As Hurthle cell carcinomas frequently have solid architecture, the high frequency of ret/PTC-3 in these tumors is not surprising.
The diagnosis and management of HCT remain controversial because of their apparently aberrant biological behavior (1, 2, 16) . HCT that have been classified as benign sometimes recur or metastasize to regional lymph nodes. These rather alarming outcomes have caused some investigators to advocate aggressive treatment for all HCT (16) . Our data indicate that more than half of the lesions that would be considered Hurthle cell adenomas according to conventional criteria, harbor ret/PTC rearrangements by RT-PCR. This implies that a substantial number of malignancies are missed when evaluated by histology alone. In light of these results, it is not surprising that many "benign" HCT recur and/or metastasize. Indeed, even in the short follow-up period that we describe, two patients with this type of tumors have had local metastases documented.
Hurthle cell carcinomas are usually compared to follicular carcinomas (2, 4). However, although some Hurthle cell car- cinomas are aggressive tumors that disseminate widely, there are many Hurthle cell carcinomas that behave in a relatively indolent fashion with a propensity for lymph node metastases. It is well recognized that PTC tend to spread via lymphatics and are generally less aggressive than their follicular counterparts. The identification of ret/PTC rearrangements in a large group of Hurthle cell carcinomas provides a molecular marker for predicting more indolent behavior and lymphatic, rather than hematogenous, spread. Indeed, 5 of the 15 tumors that we now classify as Hurthle cell PTC had lymph node metastases at the time of surgery. In contrast, the only aggressive HCC with hematogenous dissemination did not have a ret/PTC gene rearrangement. The follow-up period of these patients is too short to provide accurate clinical correlation, but our data support the hypothesis that Hurthle cell papillary carcinoma may behave in a fashion analogous to typical papillary carcinoma.
In conclusion, our data indicate that HCT includes a subgroup of lesions that exhibit nuclear features of papillary carcinoma and harbor unequivocal ret/PTC gene rearrangements. Although it is not as sensitive a technique as RT-PCR, this study confirms our previous suggestion that immunohistochemistry for ret provides a practical diagnostic tool to identify these gene rearrangements (23) . These results provide a novel molecular basis for the diagnosis of Hurthle cell PTC and represent progress in the molecular classification of human neoplasia.
